Health Care • Biotechnology: Pharmaceutical Preparations
$4.54 ▲ +0.14
(+3.07%)
MKT CAP: $171.3M • VOL: 317.3K
52W L $4 52W H $16
TRDA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $25.4M | $210.8M | $129.0M |
| YoY Revenue Growth % | -87.9% | +63.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$157.9M | $47.0M | -$3.2M |
| Operating Margin % | -80.0% | 22.3% | -2.5% |
| Net Income (GAAP) | -$143.8M | $65.6M | -$6.7M |
| EBITDA (Normalized) | -$157.1M | $49.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$128.5M | -$41.6M | $139.8M |
| Capital Expenditures (CapEx) | $1.0M | $3.2M | — |
| Free Cash Flow (FCF) | -$129.6M | -$44.7M | $139.8M |
| FCF Margin % | -80.0% | -21.2% | 80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | 11.3% | — |
| Cash & Short-Term Equivalents | $90.4M | $101.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $306.1M | $428.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TRDA.